Harry W.  Alcorn, Jr. net worth and biography

Harry Alcorn, Jr. Biography and Net Worth

Dr. Alcorn joined DiaMedica in August 2018.

Before joining DiaMedica, Dr. Alcorn served as Chief Scientific Officer of Total Renal Research, Inc., doing business as DaVita Clinical Research (DCR), a clinical research facility, from November 1997 to July 2018. While at DCR, Dr. Alcorn was responsible for clinical research operations, including management of the early clinical research unit. Dr. Alcorn also designed and created the U.S. Renal Network, the first network of Phase I renal research sites in the U.S. Dr. Alcorn developed DCR's site management organization for clinical trials. Dr. Alcorn also served as an Executive Director, a Pharmacist, and an Investigator at DCR From March 1996 to November 1997, Dr. Alcorn served as Executive Director of Clinical Programs for GalaGen, Inc., a Pharmaceutical company.  From March 1992 to March 1996, Dr. Alcorn served as Vice President, Marketing/Sales and Clinical Programs of In Home Health, Inc., a national home health provider. Dr. Alcorn served on the board of directors of Medtox Scientific Inc. 

Dr. Alcorn is also a Clinical Assistant Professor at Creighton University School of Pharmacy, Virginia Commonwealth University School of Pharmacy, University of Minnesota, College of Pharmacy, and University of Nebraska Medical Center, College of Pharmacy. Dr. Alcorn is also on the adjunct clinical faculty at the University of Colorado. Dr. Alcorn graduated from Creighton University with his B.S. in Pharmacy and received his Pharm.D. from the University of Nebraska Medical Center.

What is Harry W. Alcorn, Jr.'s net worth?

The estimated net worth of Harry W. Alcorn, Jr. is at least $119,850.50 as of September 15th, 2021. Dr. Alcorn, Jr. owns 43,582 shares of DiaMedica Therapeutics stock worth more than $119,851 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Alcorn, Jr. may own. Learn More about Harry W. Alcorn, Jr.'s net worth.

How do I contact Harry W. Alcorn, Jr.?

The corporate mailing address for Dr. Alcorn, Jr. and other DiaMedica Therapeutics executives is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. DiaMedica Therapeutics can also be reached via phone at (763) 496-5454 and via email at [email protected]. Learn More on Harry W. Alcorn, Jr.'s contact information.

Has Harry W. Alcorn, Jr. been buying or selling shares of DiaMedica Therapeutics?

Harry W. Alcorn, Jr. has not been actively trading shares of DiaMedica Therapeutics during the last quarter. Most recently, on Wednesday, September 15th, Harry W. Alcorn, Jr. bought 15,000 shares of DiaMedica Therapeutics stock. The stock was acquired at an average cost of $3.80 per share, with a total value of $57,000.00. Following the completion of the transaction, the senior vice president now directly owns 43,582 shares of the company's stock, valued at $165,611.60. Learn More on Harry W. Alcorn, Jr.'s trading history.

Who are DiaMedica Therapeutics' active insiders?

DiaMedica Therapeutics' insider roster includes Harry Alcorn, Jr. (VP), Dietrich Pauls (CEO), and Richard Pilnik (Director). Learn More on DiaMedica Therapeutics' active insiders.

Are insiders buying or selling shares of DiaMedica Therapeutics?

During the last twelve months, DiaMedica Therapeutics insiders bought shares 6 times. They purchased a total of 2,065,489 shares worth more than $6,243,249.61. The most recent insider tranaction occured on June, 23rd when Director Randall Michael Giuffre bought 65,000 shares worth more than $254,150.00. Insiders at DiaMedica Therapeutics own 6.5% of the company. Learn More about insider trades at DiaMedica Therapeutics.

Information on this page was last updated on 6/23/2023.

Harry W. Alcorn, Jr. Insider Trading History at DiaMedica Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Buy15,000$3.80$57,000.0043,582View SEC Filing Icon  
8/16/2021Buy20,322$3.09$62,794.98View SEC Filing Icon  
3/27/2019Buy150$4.46$669.00View SEC Filing Icon  
12/11/2018Buy1,000$4.00$4,000.00View SEC Filing Icon  
See Full Table

Harry W. Alcorn, Jr. Buying and Selling Activity at DiaMedica Therapeutics

This chart shows Harry W Alcorn Jr's buying and selling at DiaMedica Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DiaMedica Therapeutics Company Overview

DiaMedica Therapeutics logo
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $2.75
Low: $2.73
High: $2.80

50 Day Range

MA: $2.91
Low: $2.58
High: $3.23

2 Week Range

Now: $2.75
Low: $1.46
High: $4.75

Volume

11,656 shs

Average Volume

41,757 shs

Market Capitalization

$104.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72